Skip to content
Heart icon (animated) heart icon (static)
Share
Download Report
= Achieved

Pharmaceutical Pipeline – Key Events in 2022*

POTENTIAL APPROVALS US/EU

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory Multiple Myeloma
US
EU

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)
EU

IMBRUVICA (ibrutinib)

Pediatric Chronic Graft Versus Host Disease
US

teclistamab (BCMA/CD3)

Relapsed Refractory Multiple myeloma
US

CABENUVA

HIV Adolescents
US

STELARA (ustekinumab)

Pediatric jPSA
US

PLANNED SUBMISSIONS US/EU

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)
EU

teclistamab (BCMA/CD3)

Relapsed Refractory Multiple myeloma
EU

IMBRUVICA (ibrutinib)

Pediatric Chronic Graft Versus Host Disease
US

niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone
EU

aprocitentan

Difficult to treat hypertension
US

VAC18193

RSV Adult Vaccine
US

POTENTIAL CLINICAL DATA PRESENTATIONS

Phase III

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

IMBRUVICA (ibrutinib)

Relapsed/refractory Indolant Non-Hodgkins Lymphoma (SELENE)

niraparib

L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)

aprocitentan

Difficult to treat hypertension (PRECISION RHTT)
Phase II

BALVERSA (erdafitinib)

Tumor Agnostic (RAGNAR)

milvexian (factor Xla)

Secondary stroke prevention (AXIOMATIC-SSP)

guselkumab/golimumab

Ulcerative Colitis (VEGA)

guselkumab

Ulcerative Colitis Monotherapy (QUASAR)
*This information is accurate as of July 19, 2022 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue